Pulmonary embolism (PE) is a life-threatening condition in which a blood clot travels to the lungs, lodging in the pulmonary arteries and blocking blood flow. It is a serious medical emergency that requires prompt diagnosis and treatment. The risk factors for PE include age, gender, certain medical conditions, lifestyle choices, and family history. In this comprehensive guide, we will explore the risk factors associated with PE and discuss ways to reduce your risk.
Age is one of the most significant risk factors for developing PE. The risk of PE increases with age, with the highest risk group being those over the age of 75. This is likely due to the increased likelihood of developing other medical conditions, such as deep vein thrombosis, which can lead to the formation of a blood clot that can then travel to the lungs.
Women are at a higher risk of developing PE than men. This is likely due to the fact that women tend to have higher levels of hormones, such as estrogen, which can increase the risk of blood clotting. Additionally, women are more likely to take certain medications, such as birth control pills, which can also increase the risk of developing PE.
Certain medical conditions can increase the risk of developing PE. These include cancer, heart disease, stroke, obesity, and inflammatory bowel disease. Additionally, certain medications, such as those used to treat cancer or autoimmune diseases, can also increase the risk of PE.
Certain lifestyle choices can also increase the risk of developing PE. These include smoking, being sedentary, and being immobile for extended periods of time (such as during a long plane flight). Additionally, those who are pregnant or have recently given birth are at an increased risk of developing PE.
Having a family history of PE can also increase the risk of developing the condition. This is likely due to the fact that certain genetic factors can increase the risk of clotting. Additionally, those with a family history of certain medical conditions, such as cancer or heart disease, may also be at an increased risk of developing PE.
Although some risk factors for PE cannot be changed (such as age and family history), there are steps you can take to reduce your risk. These include: • Maintaining a healthy weight. • Exercising regularly. • Not smoking. • Taking medications as prescribed. • Avoiding long periods of immobility, such as during a long plane flight. • Wearing compression stockings if you are at an increased risk of blood clots.
Pulmonary embolism is a serious medical emergency that requires prompt diagnosis and treatment. The risk factors for PE include age, gender, certain medical conditions, lifestyle choices, and family history. By understanding the risk factors associated with PE and taking steps to reduce your risk, you can help to prevent this potentially life-threatening condition.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation